2019—2021年阜阳市人民医院抑制胃酸分泌药物的使用情况分析  

Analysis on usage of anti-gastric acid secretion drugs in Fuyang People's Hospital from 2019 to 2021

作　　者：焦浩 曹静[2] JIAO Hao;CAO Jing(Department of Pharmacy,Fuyang People’s Hospital,Fuyang 236000,China;Department of Pharmacy,Women’s Hospital of Nanjing Medical University/Nanjing Maternity and Child Health Care Hospital,Nanjing 210004,China)

机构地区：[1]阜阳市人民医院药剂科,安徽阜阳236000 [2]南京医科大学附属妇产医院/南京市妇幼保健院药学部,江苏南京210004

出　　处：《现代药物与临床》2022年第4期851-857,共7页Drugs & Clinic

基　　金：国家自然科学基金资助项目(81703100)。

摘　　要：目的分析阜阳市人民医院2019—2021年抑制胃酸分泌药物使用情况,为促进医院抑制胃酸分泌药物的合理使用及科学化管理提供参考。方法对阜阳市人民医院2019年1月—2021年12月抑制胃酸分泌药物的销售金额及构成比、抑制胃酸分泌药物的类别、药品使用频度(DDDs)、日均费用(DDC)等进行统计分析。结果阜阳市人民医院抑制胃酸分泌药物有3类,2019—2021年抑制胃酸分泌药物的销售总金额及构成比均逐年下降;质子泵抑制剂销售金额及构成比逐年下降,而H2受体阻断剂的销售金额及构成比逐年升高,3类抑制胃酸分泌药物中质子泵抑制剂的销售金额构成比一直在90%左右。在药品销售金额排名中,埃索美拉唑肠溶胶囊、注射用艾司奥美拉唑排名相对比较稳定一直处于前3名;艾普拉唑肠溶片、注射用法莫替丁销售金额排名均呈上升趋势,2021年艾普拉唑肠溶片消耗排名上升至第1位。2019—2021年DDDs排名前25位的抑制胃酸分泌药品中,雷贝拉唑钠肠溶胶囊连续2年DDDs排名第1位,艾普拉唑肠溶片、注射用法莫替丁和“4+7”抑酸药物品种奥美拉唑肠溶胶囊使用频度排名增幅显著。2019—2021年,DDC超过100元的有4种,其中艾司奥美拉唑钠粉针DDC值2019年为101.4元,2021年下降为71.66元,其他药品的DDC值均低于100元。医院内仅1/3抑制胃酸分泌药物的B/A接近于1。结论阜阳市人民医院抑制胃酸分泌药物种类齐全,使用基本合理,但个别品种在药物的选择及使用方面存在不适宜现象,提示临床医师应严格明确药物适应症指导抑酸药物的合理用药,同时药学部门需制定并开展抑酸药的点评相关工作并针对用药不合理之处积极与临床医生沟通,促进抑酸药物的合理使用。Objective To analyze the use of anti-gastric acid secretion drugs in Fuyang People's Hospital from 2019 to 2021,and provide a reference for promoting the rational use and scientific management of anti-gastric acid secretion drugs in hospital.Methods Statistical analysis was performed on the sales amount and composition ratio of anti-gastric acid secretion drugs,the types of antigastric acid secretion drugs,the frequency of drug use(DDDs),and the average daily cost(DDC)in Fuyang People's Hospital from January 2019 to December 2021.Results There were 3 types of anti-gastric acid secretion drugs in Fuyang People's Hospital,and the total consumption sum and composition ratio of anti-gastric acid secretion drugs decreased year by year from 2019 to 2021.The consumption sum and composition ratio of proton pump inhibitors decreased year by year,while the consumption sum and composition ratio of H2 receptor blockers increased,and the consumption sum ratio of proton pump inhibitors among the three types of anti-gastric acid secretion drugs had been above 90%.In the drug consumption sum ranking,Esomeprazole Enteric-soluble Capsules and Esomeprazole for injection ranked in the top 3,which was relatively stable.The consumption sum of Eprazole Enteric-coated Tablets and Motidine for injection showed an increasing trend,and the consumption sum of Eprazole Enteric-coated Tablets rose to the first place in 2021.Among the top 25 drugs for inhibiting gastric acid secretion in the list of DDDs from 2019 to 2021,Rabeprazole Sodium Enteric-soluble Capsules ranked first in DDDs for two consecutive years,Eprazole Enteric-coated Tablets,Motidine for injection and Omeprazole Enteric-soluble Capsules of"4+7"acid suppressive variety increased significantly in DDDs.From 2019 to 2021,DDC of 4 drugs exceeded 100 yuan,among which DDC value of Esomeprazole Sodium Powder was 101.4 yuan in 2019,and decreased to 71.66 yuan in 2021,and DDC value of other drugs were all below 100 yuan.There was only 1/3 of the drugs inhibiting gastric acid secretion

关 键 词：抑制胃酸分泌药物 销售金额 日均费用 用药频度 质子泵抑制剂 埃索美拉唑肠溶胶囊 

分 类 号：R975[医药卫生—药品]